Published in Cancer Weekly, March 29th, 2005
The trial is designed to evaluate the efficacy of PTK/ZK as a second-line monotherapy in patients with stage IIIB/IV non-small cell lung cancer (NSCLC). The trial, known as the GOAL Study for Growth Arrest with Oral Anti-Angiogenesis in Lung Cancer, will be conducted in France and Germany at five different sites.
This study will include patients with stage IIIB/IV NSCLC who have relapsed or are refractory to first-line therapy.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.